Mercer Global Advisors’s Travere Therapeutics TVTX Stock Holding History

Mercer Global Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$467K	Buy	8,220 +1,002	+14%	+$44.4K	﹤0.01%	2363
2026 Q1	$214K	Sell	7,218 -54	-0.7%	-$1.61K	﹤0.01%	2773
2025 Q4	$278K	Buy	+7,272	New	+$236K	﹤0.01%	2298
2020 Q2	–	Sell	-14,527	Closed	-$212K	–	1172
2020 Q1	$212K	Sell	14,527 -4,535	-24%	-$68.2K	﹤0.01%	920
2019 Q4	$271K	Buy	19,062 +2,652	+16%	+$33.9K	0.01%	957
2019 Q3	$190K	Buy	16,410 +1,639	+11%	+$27.1K	﹤0.01%	1041
2019 Q2	$297K	Buy	14,771 +341	+2%	+$6.73K	0.01%	881
2019 Q1	$327K	Buy	+14,430	New	+$319K	0.01%	789

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mercer Global Advisors's TVTX Position: Q2 2026 in Review

Mercer Global Advisors increased its Travere Therapeutics (TVTX) stake by 14% in Q2 2026, buying an estimated $44.4K and bringing the position to 8,220 shares worth $467K. The position accounts for ﹤0.01% of the portfolio, ranked #2363.

Mercer Global Advisors first reported a position in TVTX in Q1 2019 and has held it in 8 quarters since. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Mercer Global Advisors held 8,220 shares of Travere Therapeutics worth $467K as of Q2 2026.
Mercer Global Advisors bought 1,002 Travere Therapeutics shares in Q2 2026, an estimated $44.4K.
Travere Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #2363 holding.
Mercer Global Advisors first reported a position in Travere Therapeutics in Q1 2019 and has held it in 8 quarters since.
321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.